In human melanoma patients, anti-PD-1 therapeutic responses were reported to be associated with the presence of PD-1 expressing CD8+ T cells at the tumor margin, co-localized with PD-L1 expressing tumor cells before therapy [21], and therefore PD-1+ CD8+ T cells can be one of the targeted cells by anti-PD-1 mAb. The gene discussed is CD8A; the disease is melanoma.